Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is Adams Street Partners LLC's 3rd Largest Position

Adams Street Partners LLC decreased its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 26.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,129,807 shares of the company's stock after selling 402,847 shares during the quarter. Mineralys Therapeutics accounts for about 12.3% of Adams Street Partners LLC's investment portfolio, making the stock its 3rd largest position. Adams Street Partners LLC owned approximately 2.27% of Mineralys Therapeutics worth $13,908,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock worth $130,000 after purchasing an additional 989 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Mineralys Therapeutics in the fourth quarter worth about $145,000. EntryPoint Capital LLC bought a new position in shares of Mineralys Therapeutics in the fourth quarter worth about $154,000. AlphaQuest LLC lifted its position in shares of Mineralys Therapeutics by 2,637.8% during the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company's stock valued at $187,000 after buying an additional 14,666 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Mineralys Therapeutics during the 4th quarter valued at approximately $202,000. 84.46% of the stock is currently owned by institutional investors.

Mineralys Therapeutics Stock Performance

MLYS stock traded up $0.08 during midday trading on Wednesday, reaching $14.54. 161,922 shares of the company traded hands, compared to its average volume of 441,046. The firm has a market capitalization of $943.30 million, a price-to-earnings ratio of -3.97 and a beta of -0.30. Mineralys Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $18.38. The business has a 50 day moving average of $13.64 and a 200-day moving average of $12.39.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. Research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. bought 1,296,296 shares of the stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $17,499,996.00. Following the acquisition, the director now owns 4,280,051 shares of the company's stock, valued at $57,780,688.50. This represents a 43.45 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Scott Levy sold 10,757 shares of the firm's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the transaction, the chief financial officer now owns 215,340 shares in the company, valued at approximately $2,597,000.40. This represents a 4.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,213 shares of company stock valued at $1,360,567 over the last 90 days. Insiders own 33.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. HC Wainwright raised their target price on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a "buy" rating in a research note on Wednesday, April 2nd. Guggenheim restated a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, The Goldman Sachs Group cut their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a report on Thursday, February 13th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.